文献速递淋巴瘤

边缘区淋巴瘤的组织学转化:前瞻性队列研究与文献荟萃分析结果

Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.
PubMed 文献 · Blood Adv · 2024-01-01

基于分子流行病学资源(MER)队列529例边缘区淋巴瘤(MZL)患者的前瞻性数据及12项研究(6161例)的荟萃分析,评估组织学转化(HT)的累积发生率、危险因素与结局。MER队列10年HT累积发生率为3.6%,HT与死亡风险升高相关(亚分布HR 3.95),预测因素为≥2个结外部位和MALT-IPI评分≥2;荟萃分析显示5年和10年HT累积发生率分别为5%和8%,EMZL低于SMZL和NMZL。

要点

  • MER队列529例MZL患者10年HT累积发生率为3.6%,HT与死亡风险升高相关(亚分布HR 3.95,95%CI 2.06-7.55)。
  • HT预测因素为≥2个结外部位和MALT-IPI评分≥2。
  • 荟萃分析12项研究6161例患者,5年和10年HT累积发生率分别为5%和8%,EMZL低于SMZL和NMZL。

核心结论

  • HT在MZL诊断后第一个十年相对不常见,但与较差结局相关,需要新的预防和管理方法。

研究设计与样本

  • 前瞻性MER队列研究纳入2002年至2015年529例MZL患者(69%EMZL、16%SMZL、15%NMZL)。
  • 对已发表研究中HT累积发生率进行荟萃分析,纳入12项研究共6161例患者。

主要发现

  • MER队列自诊断起10年总生存率为66%。
  • MER队列中21例发生HT,5年和10年HT累积发生率分别为2.7%(95%CI 0.02-0.05)和3.6%(95%CI 0.02-0.06)。
  • HT与死亡风险升高相关(亚分布HR 3.95;95%CI 2.06-7.55)。
  • HT预测因素为≥2个结外部位和MALT-IPI评分≥2。
  • HT后5年和10年总生存率分别为79%和55%。

关键数值与推荐

  • 荟萃分析中所有亚型5年和10年HT累积发生率分别为5%(95%CI 0.05-0.06)和8%(95%CI 0.07-0.09)。
  • 荟萃分析中EMZL的5年和10年HT累积发生率分别为3%和5%。
  • 荟萃分析中SMZL的5年和10年HT累积发生率分别为7%和13%。
  • 荟萃分析中NMZL的5年和10年HT累积发生率分别为9%和13%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Marginal zone lymphoma (MZL) includes extranodal MZL (EMZL), splenic MZL (SMZL), and nodal MZL (NMZL) subtypes. Histologic transformation (HT) to large B-cell lymphomas is well documented but with a large variability in published cumulative incidence rates. We report results from the Molecular Epidemiology Resource (MER) cohort on the cumulative incidence of HT (with death as competing risk) and the associated risk factors and outcomes. We also conducted a meta-analysis of available studies on the cumulative incidence of HT. From 2002 to 2015, 529 patients with MZL were enrolled in the MER study (69% EMZL, 16% SMZL, and 15% NMZL). The 10-year overall survival (OS) from diagnosis was 66%. HT occurred in 21 patients with a 5-year and 10-year cumulative incidence of 2.7% (95% confidence interval [CI], 0.02-0.05) and 3.6% (95% CI, 0.02-0.06), respectively. HT was associated with an increased risk for death (subdistribution hazard ratio [HR], 3.95; 95% CI, 2.06-7.55). Predictors of HT were ≥2 extranodal sites and mucosa-associated lymphoid tissue International Prognostic Index score ≥2. The OS was 79% at 5 years and 55% at 10 years after HT. In the meta-analysis of 12 studies (6161 patients), the 5- and 10-year cumulative incidence of HT across all subtypes were 5% (95% CI, 0.05-0.06) and 8% (95% CI, 0.07-0.09), respectively. These rates were lower in EMZL (3% and 5%) than in SMZL (7% and 13%) and NMZL (9% and 13%). Although HT is relatively uncommon in the first decade after MZL diagnosis, it is associated with an inferior outcome and needs new approaches for prevention and management.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bommier C, Link BK, Gysbers BJ, et al. Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature. Blood Adv. 2024. PMID: 39321424. doi:10.1182/bloodadvances.2024013188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。